Related Experiment Video
Updated: Jan 5, 2026
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors
Andrey Krokhotin1, Hongwei Du2, Koichi Hirabayashi2
1Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Abstract:
Chimeric antigen receptor (CAR)-T cell-based immunotherapy of malignant disease relies on the specificity and association constant of single-chain variable fragments (scFvs). The latter are synthesized from parent antibodies by fusing their light (VL) and heavy (VH)-chain variable domains into a single chain using a flexible linker peptide. The fusion of VL and VH domains can distort their relative orientation, thereby compromising specificity and association constant of scFv, and reducing the lytic efficacy of CAR-T cells. Here, we circumvent the complications of domains' fusion by designing scFv mutants that stabilize interaction between scFv and its target, thereby rescuing scFv efficacy. We employ an iterative approach, based on structural modeling and mutagenesis driven by computational protein design. To demonstrate the power of this approach, we use the scFv derived from an antibody specific to a human leukocyte antigen A2 (HLA-A2)-HER2-derived peptide complex. Whereas the parental antibody is highly specific to its target, the scFv showed reduced specificity. Using our approach, we design mutations into scFvs that restore specificity of the original antibody.
Insights
Researchers engineered single-chain variable fragments (scFvs) for chimeric antigen receptor (CAR)-T cell therapy. Computational protein design stabilized scFv interactions, restoring specificity and enhancing CAR-T cell efficacy against malignant diseases.
Area of Science:
- Immunotherapy
- Protein Engineering
- Computational Biology
Background:
- Chimeric antigen receptor (CAR)-T cell therapy is a promising treatment for malignant diseases.
- CAR-T efficacy relies on single-chain variable fragments (scFvs) derived from antibodies.
- scFv synthesis can compromise antibody specificity and association constant, reducing CAR-T cell function.
Purpose of the Study:
- To design stabilized scFv mutants that restore the specificity and efficacy of parent antibodies.
- To overcome limitations associated with scFv domain fusion in CAR-T cell immunotherapy.
- To demonstrate a computational protein design approach for improving CAR-T cell therapeutics.
Main Methods:
- Utilized computational protein design and structural modeling for iterative mutagenesis.
- Designed scFv mutants to stabilize the interaction between the scFv and its target.
- Applied the approach to an scFv targeting a human leukocyte antigen A2 (HLA-A2)-HER2-derived peptide complex.
Main Results:
- The designed scFv mutants demonstrated stabilized interactions with the target.
- Restored specificity and association constant of the scFv to levels comparable to the parental antibody.
- Successfully rescued the efficacy of the scFv for potential use in CAR-T cells.
Conclusions:
- Computational protein design offers a viable strategy to engineer improved scFvs for CAR-T cell immunotherapy.
- Stabilizing scFv-target interactions through rational design can overcome limitations of traditional scFv synthesis.
- This approach holds potential for enhancing the therapeutic efficacy of CAR-T cells against various cancers.
